/C O R R E C T I O N — Accord BioPharma/
In the news release, Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu), issued 20-Nov-2025 by Accord BioPharma over PR Newswire, we are advised by the company that a change has been made. The complete, corrected release follows: Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and […]